Monoclonal antibody (mAb) therapy is a novel alternative treatment for
lymphoid malignancies. in this report we present a 55-year-old patient
with B-chronic lymphocytic leukemia, who was initially treated with
chlorambucil p.o. and subsequently with cyclophosphamide iv with poor
response. Then Campath-1H mAb was administered, He received three cycles
of Campath-1H, over a 3yr period, lasting 12 weeks each, at a final dose
of 30mg weekly, on an outpatient basis. After each cycle of Campath-1H
administration there was a significant decrease of the size of the
palpable lymph nodes, spleen and liver. Restoration of the blood
lymphocyte count to normal and a significant decrease of the bone marrow
lymphocytic infiltration was observed at the end of each cycle.
Therefore, a major clinical response was obtained after all cycles.
Campath-1H administration was well tolerated without causing any serious
toxicity
